Tailoring the dialysate bicarbonate eliminates pre-dialysis acidosis and post-dialysis alkalosis

BACKGROUND: Both metabolic acidosis and alkalosis increase hospitalizations, haemodynamic instability and mortality in haemodialysis patients. Unfortunately, current practices opt for a one-size-fits-all approach, leaving many patients either acidotic before or alkalotic after dialysis sessions. Therefore an individualized adjustment of these patients’ dialysate bicarbonate prescriptions could reduce these acid–base imbalances. METHODS: This is a prospective single-cohort study of patients on a chronic haemodiafiltration programme. The dialysate bicarbonate prescription was modified according to the pre- and post-dialysis total carbon dioxide (TCO(2)) values of 19–25 mEq/L and ≤29 mEq/L, respectively, with an adjustment formula calculated with the data obtained from previously published work by our group. In addition, we analysed this adjustment's effect on plasma sodium, potassium, phosphorus, parathyroid hormone (PTH) and calcium. RESULTS: At baseline, only 67.9% of patients were within the desired pre- and post-dialysis TCO(2) target range. As of the first month, every followed patient met the TCO(2) target range objective in pre-dialysis measurements and ˃95% met the post-dialysis TCO(2) target. At the end of the study, 75% of the patients were on dialysate bicarbonate of 32–34 mEq/L. There were no clinically significant changes in calcium, phosphate, PTH, sodium or potassium levels. Also, we did not notice any increase in intradialytic adverse events. CONCLUSIONS: We suggest an individualized adjustment of the dialysate bicarbonate concentration according to the pre- and post-dialysis TCO(2) values. With it, nearly every patient in our cohort reached the established range, potentially reducing their mortality risk.